Transactions 2020 | Health

Loading Events

Overview

The healthcare industry has experienced record-setting M&A and IPO volume over the last few years. From transactions within the pharma and biotech space to disruptions in healthcare services, we continue to see health related companies acquire, be acquired or IPO.  While some believe the pace of consolidation will increase, others wonder if pricing has become too expensive and appetites for deals and big dollar IPO might be fading. So is now the time to buy, sell or go public? At DirectorCorps’ annual Transactions 2020 | Health we explore these potential paths with top executives and members of the boards of leading healthcare organizations.

Agenda

  • Wednesday, June 3

    8:30 AM – 9:00 AM
    Breakfast & Registration

    9:00 AM – 9:10 AM
    Setting the Stage
    To welcome CEOs, Chairmen, board members and C-level executives to the Nasdaq MarketSite, we tee up how and why we’re exploring merger, acquisition and IPO opportunities throughout the day’s program.

    9:10 AM – 9:50 AM
    Keynote: Emerging Financial Growth Opportunities
    Robbie Huffines
    , Global Chairman, JPMorgan Chase
    Judy Lewent
    , Retired Executive Vice President & Chief Financial Officer, Merck & Co., Inc.
    The healthcare sector weaves together medical technology, healthcare services, information-driven healthcare technology, life science tools & diagnostics and pharmaceuticals. Thus, it is hard to stay on top of where the industry is headed and what kinds of deals are driving consolidation – hard, but not impossible. Indeed, this keynote session identifies the most relevant issues and trends that need to be on a leadership team’s radar.

    9:50 AM – 10:30 AM
    How to Know What Your Company is Worth
    There have been some unexpectedly high valuations by public markets and private buyers alike while other companies have floundered. Given that there is a changing evaluation of business models, disruptive technologies and significant demands for data — we look at how current market conditions, recent transaction trends and future pricing expectations might be impacted.

    10:30 AM – 10:45 AM
    Refreshment Break

    10:45 AM – 11:25 AM
    Four and a Half Strategic Deals that Make Sense
    Lindsay Androski
    , Vice President, Head of Strategic Partnering, Roivant Sciences
    Our panel of experts looks at four very different approaches to building strong companies that continue to shape the overall industry: vertical deals, traditional in-market deals, IPOs and joint ventures. Each has its risks — and potential rewards. In addition, we debate the pros and cons of co-research deals and how such ventures might impact future M&A activity.

    11:25 AM – 12:05 AM
    Regulatory and Shareholder Concerns
    Richard Mattera
    , Executive Vice President, Chief Legal Officer, Optum, Inc.
    Keith Pagnani
    , Partner, Sullivan & Cromwell LLP
    Any transaction needs to account for regulatory scrutiny. During this session, we surface the major trends impacting the industry and a few specifics to doing a deal. In addition, we talk about how much time it takes to win regulatory approval, the common objections raised by shareholders and the recent legal issues that have unexpectedly arisen from which participants can learn.

    12:05 AM – 1:00 PM
    Networking Lunch

    1:00 PM – 1:30 PM
    The New Healthcare Environment
    JPMorgan Chase, Amazon, Accenture and others have made acquisitions in the healthcare fields.  So what do these new acquirers mean for Healthcare and Life Science companies —and the industry as a whole?

    1:30 PM – 2:00 PM
    Things to Know Before the IPO
    For this year’s CEO panel, we bring together CEOs that are in the know about how to IPO. What do they wish they knew before they entered the public markets? How did they put their best foot forward as they went public? What do you need to do once you get there? These are all questions we’ll use to open this year’s panel discussion.

    2:00 PM – 2:30 PM
    Potential Growth Killers: Talent, Compensation and Culture
    Greg Arnold
    , Managing Director, Semler Brossy Consulting Group LLC
    While many laud their teams, talent and culture, we take a contrarian position during this session, talking about culture and teams, due diligence of talent in a deal and how compensation can disrupt a deal.

    2:30 PM – 2:45 PM
    Refreshment Break

    2:45 PM – 3:15 PM
    Making Great Acquisitions
    Debbie Baron, Vice President, Worldwide Business Development, Pfizer Inc.
    Andrew Rymer, Partner, Centerview Partners LLC
    Each merger is distinct — and having a tailored playbook goes a long way to aligning culture, earnings performance, resources and processes.  As we’ve seen, a successful M&A deal hinges on its structure and, by extension, how the deal was negotiated. During this session, we explore how to make great acquisitions in the coming years.

    3:15 PM – 3:45 PM
    Non-Profit Transactions
    Non-profits are an important catalyst in healthcare.  What are the notable growth trends, and what are the transactions to note?

    3:45 PM – 4:15 PM
    The Future of Healthcare
    We end our day with two experts who have seen the change in the industry. A key investor and an outspoken pundit take the stage with some food for thought.

    4:15 PM – 5:00 PM
    Networking Reception

FAQs

  • Who should attend Transactions 2020 | Health?

    Attendees include both inside and outside directors and chairmen, CEOs, CFOs and General Counsel and senior management who regularly interact with the board.

  • Why should I attend Transactions 2020 | Health?

    Be it a strategic merger or financial acquisition, the healthcare industry has experienced record-setting deal volume over the last few years.  Given transactions within the pharma and biotech space to disruptions in healthcare services, we continue to see financial sponsors seeking out new paths to grow.  While some believe the pace of consolidation will increase, others wonder if pricing has become too expensive and appetites for deals, overly exuberant. So is now the time to buy, sell or go public?  At DirectorCorps’ annual Transactions Conference, we explore these potential paths with top executives and members of the boards of leading healthcare organizations.

  • How much does this event cost, and what does the fee cover?

    The standard individual registration rate is $1295, however, attendees should contact our conference department at 877-397-7595 or events@directorcorps.com for special early and group rates. The fee includes all activities, materials and meals at the event site. This price does not include travel or hotel accommodations.

  • What if I need to cancel my reservation at the event?

    Due to commitments and expenses, all cancellations after April 27, 2020 are subject to a $200 processing fee. We regret that no refunds will be given after May 18, 2020; however, substitute participants are welcomed. DirectorCorps, Inc. assumes no liability for any nonrefundable travel, hotel or related expenses incurred by registrants.

  • What hotel options are closest to the Nasdaq MarketSite?

    Marriott Marquis Times Square
    1535 Broadway, New York, NY 10036 (212) 398-1900

    Renaissance Times Square
    Two Times Square, 714 Seventh Avenue, New York, NY 10036 (212) 765-7676

    The Roosevelt
    45 E 45th St, New York, NY 10017 (212) 661-9600

    Grand Hyatt New York
    109 E 42nd St, New York, NY 10017 (212) 883-1234

Sponsors



« Event Details

Details

Date:
June 3
Event Category:

Venue

New York
New York